Biodesix Earnings Call Signals Strong Growth Momentum

Biodesix, Inc. ((BDSX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Biodesix, Inc. struck an upbeat tone on its latest earnings call, underscoring strong revenue growth, expanding margins, and improving loss metrics that signal a constructive path toward profitability. Management acknowledged ongoing losses and some volatility, but emphasized rising demand, deeper primary care penetration, and operational leverage as key drivers of a positive long‑term trajectory.

Strong Revenue Growth

Biodesix reported Q1 2026 revenue of $25.6 million, up 42% year over year, underscoring accelerating adoption of its lung diagnostics platform. Management responded to this momentum by raising full‑year 2026 revenue guidance to a range of $108 million to $114 million, implying roughly 25% growth versus 2025 at the midpoint.

Diagnostic Testing Momentum

Diagnostic testing remained the core growth engine, generating $22.3 million in Q1 revenue, a 37% increase from the prior year. Test volumes climbed 29% to about 17,800, with primary care now accounting for 15% of total tests, signaling expanding usage beyond specialists and into broader front‑line settings.

Development Services Acceleration

The development services segment delivered a standout quarter, with revenue nearly doubling to $3.3 million, up 99% year over year. A contracted backlog of roughly $10.4 million entering the period points to sustained demand from biopharma partners and adds a visibility layer to this higher‑margin revenue stream.

Margin Expansion and Operational Efficiency

Gross margin reached 84% on a GAAP basis, or 82% excluding a $0.4 million one‑time tax recovery, representing a 300 basis‑point improvement year over year. Management attributed the gains to operating scale, better average selling prices, and lower cost per test, all of which support the case for growing profitability over time.

Improved Profitability Trajectory

While Biodesix remains in the red, loss metrics are moving in the right direction, with net loss improving to $7.8 million, a 30% year‑over‑year improvement. Adjusted EBITDA loss narrowed to $4.1 million, a 35% improvement, highlighting emerging operating leverage as revenue scales faster than key cost lines.

Strengthened Liquidity

The company ended the quarter with $25.6 million in unrestricted cash and cash equivalents, a 35% increase versus the prior quarter. This cushion was helped by $16.8 million of proceeds from at‑the‑market equity sales, giving Biodesix more flexibility to fund its growth initiatives and salesforce expansion.

Clinical Evidence and Market Recognition

Biodesix reinforced its clinical value proposition by publishing the largest lung nodule biomarker validation study, covering more than 1,100 patients and showing high specificity across nodule sizes. Additional data presentations at major oncology conferences and recognition as a top workplace for a third year in a row bolster both scientific credibility and employer brand.

Commercial Expansion Plan

The company averaged about 100 sales representatives in the field during Q1 and plans to add roughly six new reps per quarter through 2026, targeting deeper coverage and higher testing volumes. Management expects sales productivity to improve as cohorts mature, suggesting that current hiring is laying the groundwork for future revenue acceleration.

Continued Quarterly Losses

Despite notable improvements, Biodesix still posted a Q1 net loss of $7.8 million and an adjusted EBITDA loss of $4.1 million, underscoring that profitability remains a work in progress. Investors will be watching how quickly the expanding top line and margin gains can close this gap and drive sustained bottom‑line improvement.

Operating Expenses Outpacing Revenue This Quarter

Operating expenses excluding direct costs reached $27.6 million in Q1, an 18% increase year over year and a level that exceeded total revenue of $25.6 million. The company framed this as intentional, driven by a 19% rise in sales, marketing, and G&A spending aimed at supporting commercial expansion and future growth.

Development Services Timing Risk

Management cautioned that part of the Q1 development services strength reflected timing, including pull‑forward of retro sample work and earlier‑than‑expected contract revenue. While they reiterated that long‑term expectations for the business are unchanged, this nuance suggests that quarterly results in this segment may remain somewhat lumpy.

One‑time Items and ASP Volatility

The quarter benefited from a one‑time $0.4 million sales and use tax recovery, and prior periods had their own discrete items, skewing some average selling price comparisons. Management pointed out that historical collections and revenue‑cycle improvements can introduce ASP volatility, which investors should factor in when modeling margins.

Operational Disruption from Weather

Late January and early February storms, along with disruptions at a major shipping hub, temporarily affected Biodesix’s logistics and normal seasonal patterns. The episode highlighted the company’s exposure to external operational risks, even as underlying demand trends for its tests remain solid.

Cash Runway Considerations

Although the cash position improved to $25.6 million, that figure was supported by $16.8 million in equity proceeds against a backdrop of ongoing net losses and planned investments. Future cash runway will depend on maintaining growth momentum and disciplined spending, as well as the company’s ability to access capital markets if needed.

Forward‑Looking Guidance and Outlook

Management raised full‑year 2026 revenue guidance to $108 million to $114 million, citing strong Q1 trends in revenue, testing volume, and development services. The outlook calls for growth driven mainly by higher test volumes, modest ASP improvements, continued salesforce expansion, and gradual progress toward adjusted EBITDA and cash‑flow breakeven.

Biodesix’s latest earnings call painted a picture of a company scaling rapidly, backed by strong clinical data and an expanding commercial footprint, yet still navigating losses and operational noise. For investors, the setup is a classic growth story: robust top‑line expansion, improving margins, and rising liquidity, balanced against execution risks and the ongoing path to profitability.